Evofem Biosciences Inc (OTCQB:EVFM)
| 0.1399 Delayed Data As of Sep 25 |  -0.0101 / -6.73%Today’s Change | 0.12 Today|||52-Week Range 25.00 | -98.25% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $609.0K |
Company Description
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.
Contact Information
Evofem Biosciences, Inc. 7770 Regents Road San Diego California 92122 |
Employees
Shareholders
| Mutual fund holders | 0.00% |
| Other institutional | 0.00% |
| Individual stakeholders | -- |
Top Executives
| Saundra L. Pelletier | Chairman, President & Chief Executive Officer |
| Ivy Zhang | Chief Financial Officer & Secretary |
| Jason Abrams | Associate Director-Accounting Operations |
| Amy Raskopf | Head-Investor Relations |
| Ellen Thomas | Chief of Staff |
